Literature DB >> 28556296

Histological Grade and Immunohistochemical Biomarkers of Breast Cancer: Correlation to Ultrasound Features.

Frederick Wing-Fai Au1, Sandeep Ghai2, Fang-I Lu3, Hadas Moshonov4, Pavel Crystal5.   

Abstract

OBJECTIVES: The purpose of this study is to correlate various features of breast cancers on ultrasound to their histological grade and immunohistochemical biomarkers.
METHODS: Seventy-three patients with 77 invasive breast cancers, diagnosed between August 2011 and December 2014, were included in this prospective analysis. Margin, posterior features, shape, and vascularity were determined from ultrasound and classified according to the Breast Imaging Reporting and Data System lexicon. Histological grade, estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) status (positive [+] or negative [-]) were determined from surgical pathology reports. The cancers were categorized into low grade (grades 1 or 2) and high grade (grade 3). Correlation of ultrasound features of the cancers to their histological grade and receptor status was performed.
RESULTS: There were 47 low-grade and 29 high-grade cancers. There was a significant difference in margin and posterior features between the low and high grade, ER + and ER-, and PR + and PR- (all P < .05), but not between HER2 + and HER2- cancers (both P > .05). There was no significant difference in shape and vascularity among the different subtypes (all P > .05). Spiculated margin was significantly associated with low-grade, ER+, PR + status; angular margin with high grade; microlobulated margin with ER- status; shadowing with PR + status; and enhancement with high grade, ER- status (all P < .05, all odds ratios ≥ 3.94).
CONCLUSIONS: There was significant association of margin and posterior features of breast cancers with their histological grade and receptor status.
© 2017 by the American Institute of Ultrasound in Medicine.

Entities:  

Keywords:  breast; breast cancer; ultrasound

Mesh:

Substances:

Year:  2017        PMID: 28556296     DOI: 10.1002/jum.14247

Source DB:  PubMed          Journal:  J Ultrasound Med        ISSN: 0278-4297            Impact factor:   2.153


  5 in total

1.  Exosomal microRNA-551b-3p from bone marrow-derived mesenchymal stromal cells inhibits breast cancer progression via regulating TRIM31/Akt signaling.

Authors:  Ziang Yang; Bei Xu; Sheng Wu; Weige Yang; Rongkui Luo; Shengkai Geng; Zhaochen Xin; Wen Jin; Xiong Shen; Xixi Gu; Hongwei Zhang; Hong Wang
Journal:  Hum Cell       Date:  2022-08-09       Impact factor: 4.374

2.  Radiomics in predicting recurrence for patients with locally advanced breast cancer using quantitative ultrasound.

Authors:  Archya Dasgupta; Divya Bhardwaj; Daniel DiCenzo; Kashuf Fatima; Laurentius Oscar Osapoetra; Karina Quiaoit; Murtuza Saifuddin; Stephen Brade; Maureen Trudeau; Sonal Gandhi; Andrea Eisen; Frances Wright; Nicole Look-Hong; Ali Sadeghi-Naini; Belinda Curpen; Michael C Kolios; Lakshmanan Sannachi; Gregory J Czarnota
Journal:  Oncotarget       Date:  2021-12-07

3.  Comparison of clinicopathological characteristics and prognosis in breast cancer patients with different Breast Imaging Reporting and Data System categories.

Authors:  Bong Kyun Kim; Jai Min Ryu; Se Jeong Oh; Jaihong Han; Jung Eun Choi; Joon Jeong; Young Jin Suh; Jina Lee; Woo Young Sun
Journal:  Ann Surg Treat Res       Date:  2021-08-31       Impact factor: 1.859

4.  Application of preoperative ultrasound features combined with clinical factors in predicting HER2-positive subtype (non-luminal) breast cancer.

Authors:  Jin Zhou; An-Qi Jin; Shi-Chong Zhou; Jia-Wei Li; Wen-Xiang Zhi; Yun-Xia Huang; Qian Zhu; Lang Qian; Jiong Wu; Cai Chang
Journal:  BMC Med Imaging       Date:  2021-12-02       Impact factor: 1.930

5.  Stiffness in breast masses with posterior acoustic shadowing: significance of ultrasound real time shear wave elastography.

Authors:  Hui Luo; Jian Li; Yang Shi; Xiaojun Xiao; Yuanyang Wang; Zhanghong Wei; Jinfeng Xu
Journal:  BMC Med Imaging       Date:  2022-04-17       Impact factor: 2.795

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.